company background image

Delcath Systems NasdaqCM:DCTH Stock Report

Last Price


Market Cap







28 Sep, 2022


Company Financials +
DCTH fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance0/6
Financial Health2/6

DCTH Stock Overview

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.

Delcath Systems, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Delcath Systems
Historical stock prices
Current Share PriceUS$3.10
52 Week HighUS$11.95
52 Week LowUS$2.98
1 Month Change-25.84%
3 Month Change-22.31%
1 Year Change-69.37%
3 Year Change-95.96%
5 Year Change-100.00%
Change since IPO-100.00%

Recent News & Updates

Aug 05

Delcath Systems Q2 2022 Earnings Preview

Delcath Systems (NASDAQ:DCTH) is scheduled to announce Q2 earnings results on Monday, August 8th, before market open. The consensus EPS Estimate is -$1.01 (-5.2% Y/Y) and the consensus Revenue Estimate is $0.42M (-22.2% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 2 downward. Revenue estimates have seen 1 upward revision and 1 downward.

Shareholder Returns

DCTHUS Medical EquipmentUS Market

Return vs Industry: DCTH underperformed the US Medical Equipment industry which returned -31.4% over the past year.

Return vs Market: DCTH underperformed the US Market which returned -22.1% over the past year.

Price Volatility

Is DCTH's price volatile compared to industry and market?
DCTH volatility
DCTH Average Weekly Movement7.2%
Medical Equipment Industry Average Movement8.6%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: DCTH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: DCTH's weekly volatility (7%) has been stable over the past year.

About the Company

198855Gerard Michel

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma.

Delcath Systems, Inc. Fundamentals Summary

How do Delcath Systems's earnings and revenue compare to its market cap?
DCTH fundamental statistics
Market CapUS$26.65m
Earnings (TTM)-US$30.33m
Revenue (TTM)US$3.81m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DCTH income statement (TTM)
Cost of RevenueUS$571.00k
Gross ProfitUS$3.23m
Other ExpensesUS$33.57m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-3.53
Gross Margin84.99%
Net Profit Margin-797.16%
Debt/Equity Ratio-562.9%

How did DCTH perform over the long term?

See historical performance and comparison